Servier buys Edgewise muscular dystrophy business for up to US$2.65bn

Under the agreement, Servier will pay US$1.55bn upfront and up to US$1.1bn in regulatory and commercial milestones. The transaction, unanimously approved by the boards of both companies, is expected to close in the third quarter of 2026.

The deal is not a takeover of Edgewise. Servier is acquiring all rights to sevasemten, including related intellectual property, know-how, key agreements, regulatory filings and clinical data required to operate the muscular dystrophy business. Edgewise employees who primarily support the muscular dystrophy programme are expected to receive comparable offers at Servier, a move intended to ensure continuity of development and future commercial execution.

For Servier, the acquisition brings an oral, first-in-class fast skeletal myosin inhibitor into its rare neurology portfolio. Sevasemten is designed to limit the exaggerated muscle damage caused by the absence or loss of functional dystrophin, the protein whose deficiency or dysfunction drives Duchenne and Becker muscular dystrophy. The drug is being studied in late-stage clinical trials in both Becker and Duchenne muscular dystrophy.

The timing of the acquisition is significant. Edgewise’s GRAND CANYON pivotal cohort in Becker muscular dystrophy is fully enrolled with 175 participants and is expected to generate the key efficacy and safety data needed to assess the drug’s potential in the indication. Top-line data are expected in the fourth quarter of 2026. If positive, the readout could support Servier’s move into a disease where no therapy has yet been approved specifically for Becker muscular dystrophy.

Becker muscular dystrophy is a rare, X-linked genetic neuromuscular disorder that predominantly affects males and leads to progressive muscle weakness. Edgewise estimates that around 12,000 people are affected across the US, EU and Japan. Duchenne muscular dystrophy is typically more severe, beginning in early childhood and leading to progressive loss of muscle function.

Late stage asset

Sevasemten has already generated longer-term open-label data that help explain Servier’s interest. Edgewise said patients treated for more than three years in the MESA open-label extension maintained stable North Star Ambulatory Assessment scores, in contrast to the functional decline expected from Becker natural history data. The company also reported a favourable safety and tolerability profile, with no discontinuations or dose reductions due to adverse events.

The drug has also collected a series of regulatory designations. Sevasemten has received US FDA orphan drug designation for Becker and Duchenne muscular dystrophy, rare paediatric disease designation for Duchenne, and fast-track designation for both Becker and Duchenne. In Europe, it has secured EMA orphan drug designations for both indications.

The acquisition fits Servier’s stated ambition to expand in rare neurological and neuromuscular diseases. Olivier Laureau, President of Servier, said the transaction provides “an immediate platform” to expand the company’s portfolio into Becker and Duchenne muscular dystrophy and supports its 2030 ambition to become a major player in neuromuscular indications.

The muscular dystrophy field

The move also places Servier in a muscular dystrophy field that has been shaped largely by dystrophin-restoration strategies, including exon-skipping therapies. Exon-skipping drugs use antisense oligonucleotides to alter RNA splicing so that selected patients can produce a shorter, partially functional dystrophin protein. The approach is mutation-specific: each drug is designed for patients whose dystrophin mutation is amenable to skipping a particular exon, such as exon 45, 51 or 53.

Sarepta Therapeutics has led the commercial development of exon-skipping drugs in Duchenne muscular dystrophy, with products including Exondys 51, Vyondys 53 and Amondys 45 in the US. NS Pharma, part of Nippon Shinyaku, markets Viltepso for patients amenable to exon 53 skipping. More recent companies, including Dyne Therapeutics and PepGen, are trying to improve delivery of exon-skipping oligonucleotides to muscle tissue.

Sevasemten takes a different route. Rather than attempting to restore dystrophin production directly or correct the genetic reading frame, it is designed to reduce contraction-induced damage in vulnerable muscle fibres. That could make it relevant across broader Becker and Duchenne populations than mutation-specific exon-skipping drugs, although its commercial and clinical value will depend heavily on whether late-stage studies show meaningful preservation of muscle function.

Win-win scenario

For Edgewise, the transaction turns sevasemten into a major financing event and changes the company’s strategic profile. Following the closing of the deal, Edgewise said it will become a cardiovascular-focused company, with a pipeline comprising EDG-7500 for hypertrophic cardiomyopathy, EDG-15400 for heart failure with preserved ejection fraction, and EDG-003 for an undisclosed target.

The upfront proceeds, combined with Edgewise’s existing cash, are expected to fully fund EDG-7500 development through potential approval. The company remains on track to report 12-week data from Part D of the CIRRUS-HCM Phase II trial of EDG-7500 in the second quarter of 2026. Those data, covering obstructive and non-obstructive hypertrophic cardiomyopathy, are expected to inform Phase III design, with initiation targeted for the fourth quarter of 2026. Edgewise also plans to initiate a Phase II trial of EDG-15400 in heart failure with preserved ejection fraction.

The structure of the transaction therefore serves both companies. Servier gains a late-stage rare neuromuscular disease asset months before pivotal Becker data are due, while Edgewise exits muscular dystrophy with a strengthened balance sheet and a clearer focus on cardiovascular drug development.